Sentences with phrase «with dyslipidemia»

Weight loss to lower elevated levels of total cholesterol, LDL - cholesterol, and triglycerides, and to raise low levels of HDL - cholesterol, in overweight and obese persons with dyslipidemia.

Not exact matches

Prior to this role, Ryan was an Associate on the Cardio - Renal Team within the TechAtlas division of RA Capital, where he mapped competitive landscapes of drugs and medical devices for disease indications and capabilities, with a focus on coronary artery disease, stroke, and dyslipidemia.

Hyperinsulinemia is associated with hypertension, obesity, dyslipidemia, and glucose intolerance (collectively known as metabolic syndrome).

Bioactive lipids in metabolic syndrome: Scientific literature review on dietary fats and oils that help with decreasing metabolic disorders such as abdominal obesity, dyslipidemia, hypertension and insulin sensitivity that increase risk of cardiovascular disease.

In earlier publications, the researchers analysed the effects of melatonin on obesity, dyslipidemia, high blood pressure and type 2 diabetes mellitus associated with obesity in young obese diabetic Zucker rats — an experimental model of metabolic syndrome.

Sleeping in the dark and consuming these foodstuffs could help control weight gain and prevent cardiovascular diseases associated with obesity and dyslipidemia.

Previous studies had found that calcium scores were effective in predicting heart disease among adults with known heart disease risk factors, such as hypertension, diabetes, dyslipidemia, current smoking or a family history of heart disease.

NAFLD is an increasingly common condition in patients with obesity, type 2 diabetes, atherogenic dyslipidemia and arterial hypertension.

One of the greatest health concerns in developed countries is the increase in obesity, diabetes, and metabolic syndrome, which is a combination of high blood pressure (hypertension), blood sugar (hyperglycaemia), and cholesterol (dyslipidemia) along with increased belly fat.

Interestingly, recent GWASs (45 — 47) have identified SNPs near FADS1 that are associated with conditions of altered metabolism, including f - glucose, dyslipidemia, and circulating sphingolipid levels.

As recently shown in a collaborative analysis of 10 large cohort studies, women appear to feature more often the metabolically healthy obese phenotype with normoglycemia and without dyslipidemia and hypertension (7 % — 28 %) compared with males (2 % — 19 %)(39).

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Since chia seeds have such high amounts of alpha - linoleic acid and dietary fiber, scientists have tried to find out how they can help with the prevention of metabolic conditions like dyslipidemia, which is the presence of extra fat in the blood and insulin resistance, the two key reasons for developing diabetes.

For example, high - fructose diets were shown to cause dyslipidemia in healthy people with and without a family history of type II diabetes, a recent study showed15.

«Both groups improved dyslipidemia, with reduced circulating triglycerides, but showed differential responses in total and low - density lipoprotein cholesterol (decreased in LFHC group only), and high - density lipoprotein cholesterol (increased in VHFLC group only).»

Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine..

Women with PCOS tend to have higher levels of insulin and, as a result, are at an increased risk for metabolic conditions such as dyslipidemia (high triglycerides and low HDL levels), type 2 diabetes, and metabolic syndrome.

Tributyltin exposure induces gut microbiome dysbiosis with increased body weight gain and dyslipidemia in mice

Tributyltin exposure induces gut microbiome dysbiosis with increased body weight gain and dyslipidemia in mice — Hao Guo — Environmental Toxicology and Pharmacology

We also know that women with the syndrome have more inflammation as shown by higher C - reactive protein (CRP) levels and have more dyslipidemia (high triglycerides and low HDL the «good» cholesterol).

It makes sense to consider using berberine in patients with insulin resistance, pre-diabetes, diabetes, metabolic syndrome, hypertension, heart disease, dyslipidemia, cancer, depression, and other neuropsychiatric diseases.»

Testing should be considered for all individuals who are overweight or obese (BMI 25 or greater) plus the additional risks: first degree relative with diabetes mellitus or Polycystic Ovarian Disease, history of gestational diabetes, thyroid disorder, HDL level < 35 mg / dl and / or Triglyceride level > 250 mg / dl, hypertensive, sedentary, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) on previous testing, women who delivered macrosomic baby (e.g. weighing > 9 lbs), and other clinical conditions such as acanthosis nigricans, severe obesity, polycystic ovary syndrome, dyslipidemia.

Dyslipidemia is common in women with PCOS.

We all know about the variety of risk factors that have been associated with PCOS, including obesity, glucose intolerance, and dyslipidemia, which leads to a significantly increased risk for type 2 diabetes mellitus and cardiovascular disease.

It is associated with increased risk of Type 2 Diabetes Mellitus and abnormalities in blood lipid profile (dyslipidemias).

Women with PCOS frequently demonstrate many of the signs related to metabolic syndrome, such as insulin resistance, obesity, glucose intolerance, T2D, dyslipidemia and also high levels of inflammation.

The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

For a large proportion of the population, however, the effect of higher - carbohydrate diets, particularly those enriched in refined carbohydrates, coupled with the rising incidence of overweight and obesity, creates a metabolic state that can favor a worsening of the atherogenic dyslipidemia that is characterized by elevated triglycerides, reduced HDL cholesterol, and increased concentrations of small, dense LDL particles (6, 7).

Studies of atherogenic lipoprotein concentrations and properties have raised questions about the benefit of lowering saturated fat intakes by increasing carbohydrate intake, which can induce atherogenic dyslipidemia, and the benefit of increasing monounsaturated fat intakes, which does not lead to improvements in the properties of LDL particles that are associated with atherosclerosis in animal models, although substitution with monounsaturated fat rather than carbohydrate has been shown to reduce the ratio of total and LDL cholesterol to HDL cholesterol.

Sleeping in the dark and consuming these foodstuffs could help control weight gain and prevent cardiovascular diseases associated with obesity and dyslipidemia.

A few pets are just born with a tendency to high blood cholesterol and triglycerides (primary or inherited hypercholesterolemia or dyslipidemia).

Perform nutritional assessments for clients with diabetes, prediabetes, heart disease, dyslipidemia, thyroid disease, metabolic syndrome, obesity, celiac disease and other diagnoses.

Quintiles / Abbott Laboratories, Brooklyn • NY 2009 — 2011 Hospital / Dyslipidemia Representative Exceeded sales expectations for Niaspan ®, Simcor ® and Trilipix ® by building strong relationships with physicians and closing calls by using professionally assertive sales techniques.

Inclusion criteria were (1) BMI > 97th percentile for age and gender or BMI > 90th percentile20 with the presence of additional risk factors or diseases (eg, hypertension, dyslipidemia, diabetes, orthopedic problems), (2) referral for weight - reduction treatment by a local pediatrician, and (3) attendance at a regular school.